Should Your Clinic Launch Its Own Treatment Line? A Decision Guide for Malaysian Aesthetic Centres

Most aesthetic clinics and medi-spas in Malaysia already retail skincare. Usually it is a third-party professional line, stocked because patients ask what to use at home. At some point the question arises of whether to put the clinic's own name on the bottle.

It is a reasonable idea and a poor default. This guide is structured as a series of decisions rather than a recommendation, because the right answer depends on your clinic rather than the category.

Decision one: what is the line actually for?

There are three common motivations and they lead to different products. Extending post-treatment care so patients maintain results between visits points to a small, protocol-linked range. Improving retail margin points to a broader range at accessible price points. Building the clinic as a brand beyond its physical location points to something designed for online sale.

Clinics that skip this question tend to produce a range that does none of the three particularly well.

Decision two: does your patient volume support it?

Work from your own numbers. Take your monthly patient visits, apply a realistic conversion rate to home-care purchases, and compare the annual figure against a minimum order quantity and product shelf life. If the sums only work by assuming a conversion rate you have never achieved with your current retail line, the honest answer is not yet.

Decision three: how many products do you genuinely need?

A focused starting range of two or three products that map directly onto your most common treatment protocols usually outperforms a comprehensive line. Fewer SKUs means less capital tied up, fewer notifications, less shelf space and a clearer conversation in the consultation room.

Decision four: who carries the regulatory responsibility?

This one is frequently underestimated in a clinical setting. A clinic-branded cosmetic still requires NPRA notification, held by a Malaysian-registered entity, supported by a Product Information File and compliant labelling. Clinical credentials do not change these obligations, and a clinic environment makes claim discipline more important, not less. Cosmetic products cannot carry therapeutic claims regardless of who is dispensing them.

Decision five: adapt an existing formula or develop your own?

Adapting a proven library formula is faster, cheaper and lower risk, and for a first clinic range it is often entirely sufficient. Bespoke development makes sense when your protocol depends on a specific active combination that is not otherwise available, or when the line is central to how you differentiate the clinic. Both are legitimate. The mistake is paying for bespoke development to solve a problem an adapted formula would have handled.

Decision six: who is responsible after launch?

Stock control, reorder timing, renewal dates, staff training and patient questions all need an owner. In a busy clinic this rarely absorbs itself into existing roles. Name the person before the first order, not after the first stock-out.

Reaching a decision

If you have clear treatment protocols, consistent patient volume, an owner for the project and a modest initial range in mind, a clinic line is a reasonable step. If two or more of those are missing, strengthening your existing retail programme first will teach you what your patients actually buy.

Dermavelle Wellness develops private-label treatment ranges for clinics and aesthetic centres, drawing on clinical-grade formulation expertise, GMP and ISO certified production and support with packaging and regulatory documentation. If you are working through these decisions, the Dermavelle Wellness team can help you size the project realistically before you commit.